<span>Labcorp receives emergency use authorization for first non-prescription at-home collection kit for combined COVID-19, flu and RSV detection</span>
May 18, 2022

Labcorp receives emergency use authorization for first non-prescription at-home collection kit for combined COVID-19, flu and RSV detection

BURLINGTON, N.C. --(BUSINESS WIRE)--May 18, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the receipt of of Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus (RSV), a common but contagious respiratory virus often seen in children.
<span>Labcorp receives Emergency Use Authorization for at-home collection kit for combined COVID-19 and flu detection</span>
October 1, 2021

Labcorp receives Emergency Use Authorization for at-home collection kit for combined COVID-19 and flu detection

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 1, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined home collection kit that detects COVID-19 and influenza A/B simultaneously in individuals as young as 2 years of age. The kit will be available at no upfront cost to those who meet clinical guidelines, which may include experiencing symptoms, being exposed to someone with COVID-19 or if asked to be tested by a health care provider.